Arrhythmia exacerbation after sodium channel blockade in myotonic dystrophy type 1

Muscle and Nerve

Volumn 40, Issue 5, 2009, Pages 901-902

  Otten, Richard F ^a   Scherschel, John A ^a   Lopshire, John C ^a   Bhakta, Deepak ^a   Pascuzzi, Robert M ^a   Groh, William J ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROCAINAMIDE; SODIUM CHANNEL BLOCKING AGENT;

ADULT; CASE REPORT; DISEASE CLASSIFICATION; DISEASE EXACERBATION; HEART ARRHYTHMIA; HUMAN; LETTER; MALE; MYOTONIA; MYOTONIC DYSTROPHY; MYOTONIC DYSTROPHY TYPE 1; PRIORITY JOURNAL; RISK ASSESSMENT;

ADULT; ARRHYTHMIAS, CARDIAC; HUMANS; MALE; MYOTONIC DYSTROPHY; SODIUM CHANNEL BLOCKERS; SODIUM CHANNELS;

EID: 71549154363     PISSN: 0148639X     EISSN: 10974598     Source Type: Journal    
DOI: 10.1002/mus.21345     Document Type: Letter

References (13)

1. Birnberger KL, Rudel R, Struppler A. Clinical and electrophysiological observations in patients with myotonic muscle disease and the therapeutic effect of N-propyl-ajmalin. J Neurol 1975;210:99-110.
2. de Die-Smulders CE, Howeler CJ, Thijs C, Mirandolle JF, Anten HB, Smeets HJ, et al. Age and causes of death in adult-onset myotonic dystrophy. Brain 1998;121: 1557-1563. (Pubitemid 28349907)
3. Finlay M. A comparative study of disopyramide and procainamide in the treatment of myotonia in myotonic dystrophy. J Neurol Neurosurg Psych 1982;45:461-463.
4. Fitting JW, Leuenberger P. Procainamide for dyspnea in myotonic dystrophy. Am Rev Resp Dis 1989;140:1442-1445.
5. Geschwind N, Simpson JA. Procaine amide in the treatment of myotonia. Brain 1955;78:81-91.
6. Gillis AM. Class I antiarrhythmic drugs: quinidine, procainamide, disopyramide, lidocaine, mexiletine, flecainide, and propafenone. In: Zipes DP, Jalife J, editors. Cardiac electrophysiology: from cell to bedside, 4th ed. Philadelphia: W.B. Saunders; 2004:911-917.
7. Groh WJ, Lowe MR, Chandan S, Kincaid JC, Simmons Z, Ciafaloni E, et al. Electrocardiographic abnormalities and risk of sudden death in myotonic dystrophy type 1. N Engl J Med 2008;358:2688-2697.
8. Kwiecinski H, Ryniewicz B, Ostrzycki A. Treatment of myotonia with antiarrhythmic drugs. Acta Neurol Scand 1992;86: 371-375.
9. Logigian EL, Moxley RT, Blood CL, Barbieri CA, Martens WB, Wiegner AW, et al. Leukocyte CTG repeat length correlates with severity of myotonia in myotonic dystrophy type 1. Neurology 2004;62:1081-1089.
10. Lueck JD, Mankodi A, Swanson MS, Thornton CA, Dirksen RT. Muscle chloride channel dysfunction in two mouse models of myotonic dystrophy. J Gen Physiol 2007;129: 79-94. (Pubitemid 46036510)
11. Mankodi A, Logigian E, Callahan L, McClain C, White R, Henderson D, et al. Myotonic dystrophy in transgenic mice expressing an expanded CUG repeat. Science 2000;289:1769-1773.
12. Mielke U, Haass A, Sen S, Schmidt W. Antimyotonic therapy with tocainide under ECG control in the myotonic dystrophy of Curschmann-Steinert. J Neurol 1985;232:271-274. (Pubitemid 15240716)
13. Trip J, Drost G, van Engelen BG, Faber CG. Drug treatment for myotonia. Cochrane Database System Rev 2006;1: CD004762.